{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:36:24Z","timestamp":1793723784240,"version":"4.6.1"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejmech.2022.114494","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T11:35:52Z","timestamp":1653651352000},"page":"114494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Melphalan: Recent insights on synthetic, analytical and medicinal aspects"],"prefix":"10.1016","volume":"238","author":[{"given":"Rakesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-3146","authenticated-orcid":false,"given":"Rakesh","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114494_bib2","first-page":"121","article-title":"Anaesthetic challenges in cancer patients: current therapies and pain management","volume":"24","author":"Gudaityte","year":"2017","journal-title":"Acta Med. Litu."},{"key":"10.1016\/j.ejmech.2022.114494_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40580-019-0193-2","article-title":"Current trends and challenges in cancer management and therapy using designer nanomaterials","volume":"6","author":"Navya","year":"2019","journal-title":"Nano Converg."},{"key":"10.1016\/j.ejmech.2022.114494_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","article-title":"The challenge of drug resistance in cancer treatment: a current overview","volume":"35","author":"Nikolaou","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ejmech.2022.114494_bib5","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","article-title":"Challenges in diagnosis of pancreatic cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2022.114494_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ijc.31337","article-title":"Mental health of long-term survivors of childhood and young adult cancer: a systematic review","volume":"143","author":"Friend","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114494_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1517\/13543776.17.9.1061","article-title":"Alkylating agents and cancer therapy","volume":"17","author":"Ralhan","year":"2007","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114494_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0027-5107(90)90145-T","article-title":"The early history of the biological alkylating agents, 1918-1968","volume":"233","author":"Brookes","year":"1990","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ejmech.2022.114494_bib9","series-title":"Alkylating Agents","author":"Sreerama","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114494_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4615-6628-1_10","article-title":"Alkylating agents and the nitrosoureas","volume":"5","author":"Ludlum","year":"1977","journal-title":"Chemotherapy."},{"key":"10.1016\/j.ejmech.2022.114494_bib11","series-title":"Alkylating Anticancer Drugs","first-page":"71","author":"Kim","year":"2016"},{"key":"10.1016\/j.ejmech.2022.114494_bib12","first-page":"6","article-title":"Cytotoxic alpha amino acids and endopeptidases","volume":"31","author":"Bergel","year":"1953","journal-title":"Br. Emp. Cancer Ann."},{"key":"10.1016\/j.ejmech.2022.114494_bib13","first-page":"559","article-title":"L-Phenylalanine mustard (L-PAM): the first 25 Years","volume":"64","author":"Furner","year":"1980","journal-title":"Cancer Treat Rep."},{"key":"10.1016\/j.ejmech.2022.114494_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(55)92736-7","article-title":"Studies on the anti-tumour activity of p-di-(2-chloroethyl) aminophenylalanine (sarcolysine)","author":"Larionov","year":"1955","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114494_bib15","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan: a review","volume":"13","author":"Samuels","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114494_bib16","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1039\/jr9540002409","article-title":"Cyto-active amino-acid and peptide derivatives. Part I. Substituted phenylalanines","author":"Bergel","year":"1954","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114494_bib17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1039\/JR9550001223","article-title":"Cyto-active amino-acids and peptides. Part II. resolution of para Substituted Phenylalanines and synthesis of p -Di- (2-chloroeth y1) amino-DL-phenyl[\u03b2-14C] alanine","author":"Bergel","year":"1955","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114494_bib18","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1039\/JR9600003658","article-title":"Cyto-active amino-acids and peptides. part VII1.l Nu-acyl, amide, ester and peptide derivatives of melphalan","author":"Bergel","year":"1960","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114494_bib19","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1039\/jr9620003802","article-title":"Cyto-active amino acids and peptides. Part IX. Further studies of N-Acyl-dipeptides from melphalan","author":"Bergel","year":"1962","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114494_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejmech.2022.114494_bib21","first-page":"49","article-title":"Infections after high-dose chemotherapy and autologous hematopoietic stem cell transplantation","author":"Nucci","year":"2014","journal-title":"Infec Hematol."},{"key":"10.1016\/j.ejmech.2022.114494_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"322","author":"Mcelwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114494_bib23","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbmt.2012.05.011","article-title":"High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies","volume":"18","author":"Nieto","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejmech.2022.114494_bib25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14656566.2017.1349102","article-title":"Melphalan hydrochloride for the treatment of multiple myeloma","volume":"11","author":"Esma","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114494_bib26","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"J van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114494_bib28","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch \u00c4rztebl int."},{"key":"10.1016\/j.ejmech.2022.114494_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1586\/14737140.7.7.945","article-title":"Melphalan and its role in the management of patients with multiple myeloma","volume":"7","author":"Falco","year":"2007","journal-title":"Anticancer Ther."},{"key":"10.1016\/j.ejmech.2022.114494_bib29","first-page":"179","article-title":"Immunostimulatory effects of melphalan and usefulness in adoptive cell therapy with antitumor CD4+ T cells","volume":"36","author":"Kuczma","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.ejmech.2022.114494_bib30","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1401894","article-title":"Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells","volume":"194","author":"Lu","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2022.114494_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2125.2010.03638.x","article-title":"Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy","volume":"69","author":"Nath","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2125.2004.02319.x","article-title":"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation","volume":"59","author":"Nath","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib33","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A phase IIb, multicentre, open-label, safety, and efficacy study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejmech.2022.114494_bib36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clml.2019.08.013","article-title":"Pharmacokinetics and efficacy of generic melphalan is comparable to innovator formulation in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"20","author":"Pai","year":"2020","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.ejmech.2022.114494_bib39","first-page":"1","article-title":"Folate-grafted glycyl-glycine-melphalan conjugate self-assembled amphilphilc nanomicelles augmented drug delivery, cytotoxicity and cellular uptake in human ovarian cancer cells","author":"Duan","year":"2020","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejmech.2022.114494_bib40","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1200\/JCO.1988.6.11.1768","article-title":"The systemic administration of intravenous melphalan","volume":"6","author":"Sarosy","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114494_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","article-title":"Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review","volume":"15","author":"Hossen","year":"2018","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejmech.2022.114494_bib42","first-page":"16","article-title":"Synthesis and evaluation of multi layered magnetic nanoparticles as versatile carrier for anti-cancer drug delivery","volume":"10","author":"Latha","year":"2020","journal-title":"Int. J. Life Sci. Pharma Res."},{"key":"10.1016\/j.ejmech.2022.114494_bib43","first-page":"102","article-title":"Investigation of characterization and cytotoxic effect of PEGylated nanoliposomal containing melphalan on ovarian cancer: an in vitro study","volume":"16","author":"Mirnezamia","year":"2021","journal-title":"J. Exp. Nanosci."},{"key":"10.1016\/j.ejmech.2022.114494_bib44","first-page":"1","article-title":"In vitro and in vivo assessment of designed melphalan loaded stealth solid lipid nanoparticles for parenteral delivery","volume":"15","author":"Pavan Rudhrabatla","year":"2018","journal-title":"Bio. Nano Sci."},{"key":"10.1016\/j.ejmech.2022.114494_bib58","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cclet.2018.02.010","article-title":"Bone-targeting melphalan prodrug with tumor-microenvironment sensitivity: synthesis, in vitro and in vivo evaluation","volume":"26","author":"Chen","year":"2018","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114494_bib59","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3390\/jcm9103120","article-title":"Melflufen: a peptide\u2013drug conjugate for the treatment of multiple myeloma","volume":"9","author":"Mateos","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2022.114494_bib60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-1-4615-1173-1_15","article-title":"Clinical pharmacological of melphalan and its implications for clinical resistance to anticancer agents","volume":"112","author":"Jones","year":"2002","journal-title":"Cancer Treat Res."},{"key":"10.1016\/j.ejmech.2022.114494_bib45","first-page":"23","article-title":"The targeted delivery of cancer drugs across the blood\u2013brain barrier: chemical modifications of drugs or drug-nanoparticles","volume":"13","author":"Jeanneret","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114494_bib46","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/03639045.2018.1449857","article-title":"Water-soluble porphyrin-PAMAM-conjugates of melphalan and their anticancer activity","volume":"44","author":"Ramirez-Arroniz","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejmech.2022.114494_bib47","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies-current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2022.114494_bib48","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3109\/03639045.2012.702346","article-title":"Synthesis, characterization and in vitro studies of pegylated melphalan conjugates","volume":"39","author":"Ajazuddin","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejmech.2022.114494_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2019.109350","article-title":"Melphalan-monomethoxypolyethylene glycol-based pH\/enzyme doubleresponse polymer prodrug nanoparticles for enhanced drug stability and anticancer efficacy","volume":"122","author":"Wu","year":"2020","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.ejmech.2022.114494_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101098","article-title":"One-step and facile synthesis of peptide-like poly(melphalan) nanodrug for cancer therapy","volume":"37","author":"Zhang","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.ejmech.2022.114494_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.carbpol.2013.04.071","article-title":"Preparation, characterization, and in vitro efficacy of O-carboxymethyl chitosan conjugate of melphalan","volume":"98","author":"Lu","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejmech.2022.114494_bib52","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.carbpol.2014.04.062","article-title":"A novel melphalan polymeric prodrug: preparation and property study","volume":"111","author":"Li","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejmech.2022.114494_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.110759","article-title":"Electrosprayed nanoparticles of poly(p-dioxanone-co-melphalan) macromolecular prodrugs for treatment of xenograft ovarian carcinoma","volume":"111","author":"Wen","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejmech.2022.114494_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0168-3659(91)90036-D","article-title":"Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N- (2-hydroxypropyl) methacrylamide copolymers","volume":"16","author":"Duncan","year":"1991","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2022.114494_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1773-2247(09)50007-X","article-title":"Liposomes loaded with lipophilic prodrugs of methotrexate and melphalan as convenient drug delivery vehicles","volume":"19","author":"Kuznetsova","year":"2009","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2022.114494_bib56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.carbpol.2014.12.057","article-title":"Synthesis and in vitro evaluation of a hyaluronic acid\u2013quantum dots\u2013melphalan conjugate","volume":"121","author":"Xu","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejmech.2022.114494_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157017808783955862","article-title":"Synthesis of Melphalan-gem-bisphosphonate conjugation to bone tumors and study of affinity to hydroxyapatite in vitro","volume":"5","author":"Jiang","year":"2008","journal-title":"Lett. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib61","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejps.2013.08.007","article-title":"A Polyphosphoester conjugate of melphalan as antitumoral agent","volume":"50","author":"Bogomilova","year":"2013","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2022.114494_bib62","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s10637-011-9663-z","article-title":"Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies","volume":"30","author":"Peyrode","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2022.114494_bib63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1021\/bc020031e","article-title":"Synthesis and in vivo biodisposition of [14C]-quaternary ammonium-melphalan conjugate, a potential cartilage-targeted alkylating drug","volume":"14","author":"Rapp","year":"2003","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib64","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1021\/jm010926x","article-title":"Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma","volume":"45","author":"Giraud","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bcp.2006.04.028","article-title":"Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells","volume":"72","author":"Bielawski","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib66","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0014-827X(03)00164-2","article-title":"Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells","volume":"58","author":"Chrzanowski","year":"2003","journal-title":"Farmaco"},{"key":"10.1016\/j.ejmech.2022.114494_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/mp049922p","article-title":"Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs","volume":"2","author":"Mittal","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2022.114494_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/bc970163l","article-title":"Development and activities of a new melphalan prodrug designed for tumor-selective activation","volume":"9","author":"Kerr","year":"1998","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib69","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jlcr.3575","article-title":"Synthesis, 99m Tc-labeling, and preliminary biological evaluation of DTPA-melphalan conjugates","volume":"60","author":"Wang","year":"2017","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2022.114494_bib70","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bioorg.2017.01.020","article-title":"Synthesis of dual-action parthenolide prodrugs as potent anticancer agents","volume":"71","author":"Taleghani","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib71","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s10967-016-4955-6","article-title":"Synthesis and biological studies of 99mTc (HYNIC\u2013MFL) (tricine)(TPPTS) as a novel tumor imaging agent","volume":"310","author":"Wang","year":"2016","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib72","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1248\/cpb.58.332","article-title":"Novel melphalan and chlorambucil derivatives of 2,2,6,6-tetramethyl-1- piperidinyloxy radicals: synthesis, characterization, and biological evaluation in vitro","volume":"58","author":"Zhao","year":"2010","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2022.114494_bib73","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.ejmech.2011.02.008","article-title":"Bivalent bendamustine and melphalan derivatives as anticancer agents","volume":"46","author":"Scutaru","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib74","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1039\/JR9590000097","article-title":"Cyto-active amino-acids and peptides. Part V1.l Synthesis of N\u2018- a - aminoacyl-NN-di- (2-chZoroethyZ) -p -phenylenediamines","author":"Bergel","year":"1959","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114494_bib75","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1039\/jr9620003806","article-title":"Cyto-active amino-acids and peptides. Part X. A pentapeptide and a basic dipeptide from melphalan","author":"Johnson","year":"1962","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114494_bib76","first-page":"2564","article-title":"Cyto-active amino-acids and peptides. part XV.l the synthesis of p-Di-(2-chloroethyl) aminophenyl-L-alanine (Melphalan) labelled with tritium","author":"Wade","year":"1968","journal-title":"J. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114494_bib77","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s002800050742","article-title":"The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site","volume":"41","author":"Timar","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib78","first-page":"1972","article-title":"Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups","volume":"89","author":"Janaky","year":"1992","journal-title":"Proc. Nati. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114494_bib79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00008390-199106000-00005","article-title":"Human melanoma targeting with \u03b1-MSH -melphalan conjugate","volume":"1","author":"Ghanem","year":"1991","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ejmech.2022.114494_bib80","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1749-6632.1993.tb19697.x","article-title":"Attempts to use a-melanotropin-containing melphalan in melanoma patients","volume":"680","author":"Lejeune","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2022.114494_bib81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10611869709017893","article-title":"Derivatives of melphalan designed to enhance drug accumulation in cancer cells","volume":"4","author":"Kupczyk-Subotkowska","year":"1997","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejmech.2022.114494_bib82","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0006-2952(62)90167-3","article-title":"Haemotological and tumour-inhibitory effects of peptide derivatives of melphalan","volume":"11","author":"Elson","year":"1962","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib83","first-page":"1","article-title":"Melphalan, alone or conjugated to an FSH-b peptide, kills murine testicular cells in vitro and transiently suppresses murine spermatogenesis in vivo","author":"Amory","year":"2014","journal-title":"Theriogenology"},{"key":"10.1016\/j.ejmech.2022.114494_bib84","doi-asserted-by":"crossref","DOI":"10.1097\/00001813-200309000-00006","article-title":"Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan","volume":"14","author":"Gullbo","year":"2003","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2022.114494_bib85","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/13543784.2020.1808884","article-title":"Melflufen for relapsed and refractory multiple myeloma","volume":"29","author":"Oriol","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114494_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101374","article-title":"The approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA","volume":"18","author":"Olivier","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2022.114494_bib87","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12885-016-2299-9","article-title":"In vitro and in vivo activity of melflufen (J1) in lymphoma","volume":"16","author":"Delforoush","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2022.114494_bib88","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/acs.oprd.9b00116","article-title":"Development of a safe process for manufacturing of the potent anticancer agent melflufen hydrochloride","volume":"23","author":"Cotton","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2022.114494_bib89","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3727\/000000003771013071","article-title":"Structure\u2013activity relationship for alkylating dipeptide nitrogen mustard derivatives","volume":"14","author":"Gullbo","year":"2003","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2022.114494_bib90","first-page":"69","article-title":"Simaltaneous determination of melphalan and its process related impurities using a stability indicating and validated. Reverse phase HPLC method in short run time","volume":"12","author":"Rao","year":"2017","journal-title":"IOSR J. Pharm."},{"key":"10.1016\/j.ejmech.2022.114494_bib91","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1556\/AChrom.20.2008.3.6","article-title":"An isocratic UV HPLC assay for analysis of total and free melphalan concentration in human plasma","volume":"20","author":"Nath","year":"2008","journal-title":"Acta Chromatogr."},{"key":"10.1016\/j.ejmech.2022.114494_bib92","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1021\/bc900453f","article-title":"Optimization of the N-Lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agent","volume":"21","author":"Scutaru","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121711","article-title":"Measurement of DNA alkylating agents busulfan and melphalan in human plasma by mass spectroscopy","volume":"1125","author":"Schofield","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejmech.2022.114494_bib94","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1016\/j.jchromb.2009.07.033","article-title":"Assay for the quantification of melphalan and its hydrolysis product in human plasma by liquid chromatography-tandem mass spectroscopy","volume":"877","author":"Mirkou","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejmech.2022.114494_bib95","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/BF02493133","article-title":"Rapid determination of the anti-cancer drug melphalan (Alkeran) in human serum and plasma by automated solid phase extraction and liquid chromatography tandem mass spectroscopy","volume":"52","author":"Davies","year":"2000","journal-title":"Chromatographia"},{"key":"10.1016\/j.ejmech.2022.114494_bib96","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1080\/01483919008049568","article-title":"Liquid chromatographic analysis of plasma melphalan with amperometric detection in a patient with breast cancer","volume":"13","author":"Malecki","year":"1990","journal-title":"J. Liq. Chromatogr."},{"key":"10.1016\/j.ejmech.2022.114494_bib97","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0378-4347(91)80054-G","article-title":"Quantitation of melphalan in plasma of patients by reversed phase high-performance liquid chromatography with electrochemical detection","volume":"563","author":"Silvestro","year":"1991","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.ejmech.2022.114494_bib98","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s11095-007-9249-9","article-title":"Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma","volume":"24","author":"Mittal","year":"2007","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2022.114494_bib99","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0378-4347(00)84146-8","article-title":"Quantitative analysis of melphalan and its major hydrolysate in patients and animals by reverse phase high performance liquid chromatography","volume":"222","author":"Ahmed","year":"1981","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.ejmech.2022.114494_bib100","doi-asserted-by":"crossref","first-page":"316","DOI":"10.5530\/ijper.53.2.40","article-title":"Development and validation of an HPLC-UV method for the determination of melphalan from lyophilized nanosuspension","volume":"53","author":"Ananda","year":"2019","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"10.1016\/j.ejmech.2022.114494_bib101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-4347(96)00184-3","article-title":"High-performance liquid chromatographic assay for melphalan in human plasma application to pharmacokinetic studies","volume":"686","author":"Pingue","year":"1996","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejmech.2022.114494_bib102","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.chroma.2017.02.015","article-title":"Analyzing complex mixtures of drug-like molecules: ion mobility as an adjunct to existing liquid chromatography-(tandem) mass spectrometry method","volume":"1490","author":"Boschmans","year":"2017","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejmech.2022.114494_bib103","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jalm\/jfaa237","article-title":"Paperspray ionization mass spectrometry as a tool for predicting real-time optimized dosing of the chemotherapeutic drug melphalan","volume":"6","author":"Zhao","year":"2021","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.ejmech.2022.114494_bib104","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF00256176","article-title":"The effect of food on oral melphalan absorption","volume":"16","author":"Reece","year":"1986","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0014-2964(78)90253-0","article-title":"Pharmaco-kinetics of melphalan following oral or intravenous administration an patients with malignant disease","volume":"14","author":"Tattersall","year":"1978","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114494_bib106","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF00254244","article-title":"Renal clearance and protein binding of melphalan in patients with cancer","volume":"22","author":"Reece","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib107","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2012.01.027","article-title":"Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan","volume":"426","author":"Rajpoot","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2022.114494_bib108","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2018.04.001","article-title":"Therapeutic journery of nitrogen mustard as alkylating anticancer agents: historic to future perspectives","volume":"151","author":"Singh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114494_bib109","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00542192","article-title":"Melphalan concentration dependent plasma protein binding in healthy humans and rats","volume":"32","author":"Greig","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib110","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/jps.2600710729","article-title":"Degradation of melphalan in aqueous solutions-influence of human albumin binding","volume":"71","author":"Ehrsson","year":"1982","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2022.114494_bib111","first-page":"1","article-title":"Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma","volume":"36","author":"Morival","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114494_bib112","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/bcp.13774","article-title":"Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a revaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function","volume":"85","author":"Duong","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-003-0761-2","article-title":"Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies","volume":"53","author":"Mougenot","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib114","first-page":"237","article-title":"Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer","volume":"15","author":"Mougenot","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2022.114494_bib115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0609.2012.01795.x","article-title":"Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma","volume":"89","author":"Talamo","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2022.114494_bib116","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bbmt.2020.03.008","article-title":"PARP inhibition synergizes with melphalan but does not reverse resistance completely","volume":"20","author":"Patel","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejmech.2022.114494_bib117","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple Myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114494_bib118","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2022.114494_bib119","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114494_bib120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10238-019-00587-2","article-title":"Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells","volume":"20","author":"Tabata","year":"2021","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2022.114494_bib121","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/17425255.2019.1552256","article-title":"Drug\u2013drug interactions in patients receiving hematopoietic stem cell transplantation","volume":"15","author":"Pejcic","year":"2019","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2022.114494_bib122","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00001813-199112000-00007","article-title":"Interaction of melphalan and dexamethasone in human myeloma cell line","volume":"2","author":"fernberg","year":"1991","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2022.114494_bib123","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.1978.173","article-title":"Effects of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide","volume":"38","author":"Millar","year":"1978","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114494_bib124","series-title":"Tulane Health Sciences Center","author":"Rider","year":"2007"},{"key":"10.1016\/j.ejmech.2022.114494_bib125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00253974","article-title":"Interaction of cimetidine with oral melphalan","volume":"20","author":"Sviland","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib126","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s002800050611","article-title":"Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid","volume":"39","author":"Pruijn","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib127","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3892\/mco.2015.683","article-title":"The interaction between oral melphalan and gastric antisecretory drugs: impact on clinical efficacy and toxicity","volume":"4","author":"Kitazawa","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114494_bib128","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114494_bib129","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00570497","article-title":"Effect of L-leucine on oral melphalan kinetics in patients","volume":"20","author":"Reece","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114494_bib130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ophtha.2013.10.045","article-title":"Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma","volume":"121","author":"Taich","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2022.114494_bib131","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ejmech.2022.114494_bib132","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archsurg.1995.01430010045009","article-title":"Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs","volume":"130","author":"Vrouenraets","year":"1995","journal-title":"Arch. Surg."},{"key":"10.1016\/j.ejmech.2022.114494_bib133","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<224::AID-SSU6>3.0.CO;2-A","article-title":"Toxicity and morbidity of isolated limb perfusion","volume":"14","author":"Vrouenraets","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114494_bib134","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/801495","article-title":"Secondary primary malignancies in multiple myeloma: an old nemesis revisited","author":"Yang","year":"2012","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.ejmech.2022.114494_bib135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0163-7258(97)82004-9","article-title":"Cytotoxic therapy and pregnancy","volume":"74","author":"Ebert","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114494_bib136","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13287-020-01984-1","article-title":"Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells","volume":"11","author":"Liu","year":"2020","journal-title":"Stem Cell Res. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114494_bib137","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tid.12037","article-title":"Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis","volume":"15","author":"Taimur","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114494_bib138","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114494_bib139","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1179\/1973947814Y.0000000231","article-title":"Encephalopathy following melphalan administration","volume":"29","author":"Dubey","year":"2017","journal-title":"J. Chemother."},{"key":"10.1016\/j.ejmech.2022.114494_bib140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21276\/apjhs.2020.7.2.2","article-title":"Expression of Bax and Bcl-2 apoptotic regulatory proteins in melphalan-induced spermatogenic dysfunction","volume":"7","author":"Omolara Ojo","year":"2020","journal-title":"Asian Pac. J. Health Sci."},{"key":"10.1016\/j.ejmech.2022.114494_bib141","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ophtha.2020.09.021","article-title":"Risk factors for acute chorzoidal ischemia after intra-arterial melphalan for retinoblastoma: the role of the catheterization approach","volume":"128","author":"Stathopoulos","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejmech.2022.114494_bib142","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40265-021-01522-0","article-title":"Melphalan flufenamide (melfufen): first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114494_bib144","first-page":"1","article-title":"Melflufen, a peptide-conjugated alkylator, is an efficient anti-neoplastic drug in breast cancer cell line","author":"Schepsky","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejmech.2022.114494_bib145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/1120009X.1994.11741157","article-title":"Study of lymphotropic targeting and macrofilaricidal activity of a melphalan prodrug on the molinema dessetae model","volume":"6","author":"Loiseau","year":"1994","journal-title":"J. Chemother."},{"key":"10.1016\/j.ejmech.2022.114494_bib146","first-page":"1153","article-title":"Synthesis of the orally macrofilaricidal and stable glycerolipidic prodrug of melphalan, 1,3-dipalmitoyl-2-(4'(bis(2''-chloroethyl)amino)phenylalaninoyl)glycerol","volume":"42","author":"Deverre","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejmech.2022.114494_bib147","series-title":"A Review of Human Carcinogens, Pharmaceuticals Volume 100 A, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","year":"2012"},{"key":"10.1016\/j.ejmech.2022.114494_bib148","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.bmt.1702806","article-title":"Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma","volume":"27","author":"Vassal","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ejmech.2022.114494_bib149","series-title":"Melflufen Dosage Regimens for Cancer, WO 2017\/093443 Al","author":"Lindberg","year":"08062017"},{"key":"10.1016\/j.ejmech.2022.114494_bib150","series-title":"Parenteral Formulations of Melphalan, WO 2017\/085696 Al","author":"Kocherlakota","year":"26052017"},{"key":"10.1016\/j.ejmech.2022.114494_bib151","series-title":"Stable Liquid Formulations of Melphalan, WO 2017\/002030 Al","author":"Chandrashekhar","year":"05012017"},{"key":"10.1016\/j.ejmech.2022.114494_bib152","series-title":"US 2016\/0090352 A1","author":"Claudio","year":"31032016"},{"key":"10.1016\/j.ejmech.2022.114494_bib153","series-title":"Process for the Preparation of Melphalan Hydrochloride, US 8921596 B2","author":"Gurjar","year":"30122014"},{"key":"10.1016\/j.ejmech.2022.114494_bib154","series-title":"An Improved Process for the Synthesis of Melphalan and the Hydrochloride Salt, WO 2014\/141294 A2","author":"Pullagurla","year":"18092014"},{"key":"10.1016\/j.ejmech.2022.114494_bib155","series-title":"Lyophilized Preparations of Melphalan Flufenamide, WO 2014\/065751 Al","author":"Spira","year":"01052014"},{"key":"10.1016\/j.ejmech.2022.114494_bib156","series-title":"Bisphosphonate Prodrugs, WO 2012\/113571 Al","author":"Kratz","year":"30082012"},{"key":"10.1016\/j.ejmech.2022.114494_bib157","series-title":"Injectable Formulation of Melphalan, WO 2012\/004438 Al","author":"Castillo","year":"12012012"},{"key":"10.1016\/j.ejmech.2022.114494_bib158","series-title":"A Composition Comprising of Melphalan Derivatives and Gemcitabine or Etoposide Useful in Treatment of Cancer, WO 2011\/078782 A1","author":"Gullbo","year":"30062011"},{"key":"10.1016\/j.ejmech.2022.114494_bib159","series-title":"Process for Making Optically Pure Melphalan, WO 2009\/117164","author":"Jobdevairakkam","year":"20032009"},{"key":"10.1016\/j.ejmech.2022.114494_bib160","series-title":"Melphalan Derivatives and Their Use as Cancer Chemotherapeutic, US 6992207 B2","author":"Rolf","year":"31012006"},{"key":"10.1016\/j.ejmech.2022.114494_bib161","series-title":"Melphalan Prodrugs, WO2005\/070457 A1","author":"Toki","year":"04082005"},{"key":"10.1016\/j.ejmech.2022.114494_bib162","series-title":"Conjugates of Porphyrin Compounds with Chemotherapeutic Agents, US 2004\/0192665 A1","author":"Frydman","year":"30092004"},{"key":"10.1016\/j.ejmech.2022.114494_bib163","series-title":"Prodrugs for Beta-Lactamase and Uses Thereof, EP 0 484 870 A2","author":"Kadow","year":"13051992"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:13:59Z","timestamp":1728382439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422003968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":156,"alternative-id":["S0223523422003968"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114494","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Melphalan: Recent insights on synthetic, analytical and medicinal aspects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114494"}}